The treatment of pancreatic cancer is challenging. Patients are often beyond curative
surgical therapy and palliative treatment with chemotherapy provides limited benefit.
New markers of cancer activity and therapeutic targets are required.
This thesis has firstly reviewed the available literature on Tumour M2-PK, a dimeric
form of M2 isoenzyme of pyruvate kinase, in GI cancer and carried out a meta-analysis
of the clinical data on pancreatic cancer. Experimental work evaluated the measurement
of M2-pyruvate kinase in human pancreatic cancer cell lines with altered
microenvironment (hypoxia, acidic pH or glucose-deprived condition). Tumour M2-PK
level was measured using ELISA, total M2-PK by immunoblotting and pyruvate kinase
activity by spectrophotometric analysis. Apoptosis or necrosis was detected by measuring
active Caspase 3/7 and 8, Bcl-2, Bax and Annexin V staining. Localisation of M2-PK in
pancreatic cancer cell was studied by immunocytochemistry.
The clinical review has shown that Tumour M2-PK is not an organ-specific marker of GI
cancer but is elevated with positive predictive value of 86β88% in gastro-oesophageal
and colorectal cancers. In pancreatic cancer the diagnostic odds ratio (DOR) of an
elevated Tumour M2-PK was similar to those of CA19-9 with overall sensitivity of 94%
and specificity of 55%. Higher levels of Tumour derived M2-pyruvate kinase were
observed in Colo 357 cell lines compared to Panc-1 cells. Exposure of Colo 357 cells to
altered culture conditions resulted in decreased cell proliferation accompanied by
elevated Tumour M2-PK levels with unchanged total M2-PK levels suggesting tetramerdimer switch-over, which was confirmed by the corresponding change in the pyruvate
kinase activity. No correlation of Tumour M2-PK level or PK activity with apoptotic or
anti-apoptotic markers was observed. Immunocytochemistry suggested M2-PK
localisation to intracellular membrane-bound structures with no translocation to nucleus
or mitochondria under altered tumour microenvironment.
Conclusion: Tumour M2-PK is a potential marker of pancreatic cancer. Altering the
tumour microenvironment causes a switch to measured M2-PK levels. This may allow
cells to overcome cell apoptosis and could be a pathway facilitating tumour survival
Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.